| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3 | - | ||
| Other current assets | 2 | 8 | ||
| Cash and cash equivalents | - | 20 | ||
| Total current assets | 5 | 28 | ||
| Fixed assets, net | 2 | 2 | ||
| Total assets | 7 | 30 | ||
| Short-term credit from a related party-Related Party | 41 | 41 | ||
| Other account payables and accrued expenses | 475 | 473 | ||
| Payable to related party-Related Party | 755 | 564 | ||
| Total current liabilities | 1,271 | 1,078 | ||
| Common stock, 0.01 par value authorized 50,000,000 shares at september 30, 2025, and december 31, 2024 issued and outstanding 19,626,418 and 18,701,418 at september 30, 2025 and december 31, 2024, respectively | 196 | 196 | ||
| Additional paid-in capital | 8,435 | 8,396 | ||
| Accumulated deficit | -9,895 | -9,640 | ||
| Total stockholders equity (deficit) | -1,264 | -1,048 | ||
| Total liabilities and stockholders equity (deficit) | 7 | 30 | ||
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)